119,193 results match your criteria liver transplantation


Secular Trends in Severe Idiosyncratic Drug Induced Liver Injury in North America: An Update from the ALFSG Registry.

Am J Gastroenterol 2022 Jan 25. Epub 2022 Jan 25.

Department of Internal Medicine, UT Southwestern Medical Center at Dallas, TX.

Background: Idiosyncratic drug-induced liver injury (DILI) is the second-leading cause of acute liver failure (ALF) in the US. Our study aims were to characterize secular trends in the implicated agents, clinical features, and outcomes of adults with DILI ALF over a 20-year period.

Methods: Among 2,332 ALF patients enrolled in the Acute Liver Failure Study Group registry, 277 (11. Read More

View Article and Full-Text PDF
January 2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Blood 2022 Jan 26. Epub 2022 Jan 26.

Johns Hopkins University, Baltimore, Maryland, United States.

The phase 3 ADMIRAL trial demonstrated superior overall survival (OS) in relapsed/refractory FLT3-mutation-positive acute myeloid leukemia patients randomized 2:1 to the oral FLT3 inhibitor, gilteritinib, versus those randomized to salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to clarify the long-term treatment effects and safety of gilteritinib. At the time of this analysis, the median survival follow-up was 37. Read More

View Article and Full-Text PDF
January 2022

Experimental study to assess the impact of vasopressors administered during maintenance of the brain-dead donation in the quality of the intestinal graft.

J Trauma Acute Care Surg 2022 Feb;92(2):380-387

From the Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP-CONICET-UNLP) (L.E.V.D., D.E.R., I.M.I.M., J.V., P.L.S., M.R.), Universidad Nacional de La Plata, La Plata, Argentina; Cátedra de Trasplante de Órganos (L.E.V.D., J.C.A.Z., N.R.L., P.L.S.), Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina; Laboratorio de Patología Especial (M.A.M.), Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Argentina; Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMETTYB-CONICET) (G.E.G.), Buenos Aires, Argentina; and Instituto de Trasplante Multiorgánico (G.E.G.), Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina.

Background: The hemodynamic maintenance of brain-dead donors will influence the quality of the organs procured for transplantation, including the intestine. Although norepinephrine (NE) and dopamine (DA) are commonly used to sustain mean arterial pressure in humans, there are no standardized protocols for their use during maintenance of brain-dead donors. Our aim was to compare the effects of each drug, in the intestinal graft quality using a rat brain-dead donation model. Read More

View Article and Full-Text PDF
February 2022

Finding the Right Balance in Pregnancy After Liver Transplantation: The Graft Function Should Also Be Taken Into Account.

Am J Gastroenterol 2022 Jan 26. Epub 2022 Jan 26.

Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

View Article and Full-Text PDF
January 2022

Liver transplantation as a treatment for Wilson's disease with neurological presentation: a systematic literature review.

Acta Neurol Belg 2022 Jan 26. Epub 2022 Jan 26.

Second Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957, Warsaw, Poland.

Introduction: Wilson's disease (WD) is a potentially treatable, genetic disorder of copper metabolism, with survival similar to healthy populations if controlled. However, in almost 50% of WD patients, neurological symptoms persist despite treatment, and in up to 10% of patients, neurological deterioration is irreversible. International guidelines on WD treatment do not recommend liver transplantation (LT) as a treatment for neurological symptoms in WD. Read More

View Article and Full-Text PDF
January 2022

Resveratrol Alleviates Hepatic Fibrosis in Associated with Decreased Endoplasmic Reticulum Stress-Mediated Apoptosis and Inflammation.

Inflammation 2022 Jan 26. Epub 2022 Jan 26.

Biomedical Research Center, Institute for Clinical Sciences, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Hepatic fibrosis (HF) is the typical response to chronic liver disease and is characterized by deposition of abundant extracellular matrix. The aim of the present study was to investigate the protective effect of resveratrol (RSV) in a CCl-induced rat model of HF. We demonstrate that the administration of RSV effectively improves liver function and ameliorates liver fibrosis by reducing collagen deposition and reversing the expression of COL1A1 and PPAR-γ. Read More

View Article and Full-Text PDF
January 2022

[Resection and transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma].

Radiologe 2022 Jan 26. Epub 2022 Jan 26.

Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Leipzig, Leipzig, Deutschland.

Clinical Issue: Treatment of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) has markedly improved in recent years.

Standard Treatment: Liver resection and, for HCC, liver transplantation are essential components of curative treatment in the nonmetastatic stage.

Treatment Innovations: In the current S3 guideline, the role of the interdisciplinary tumor board is strengthened for the individual therapy decision. Read More

View Article and Full-Text PDF
January 2022

Liver Transplantation for Hepatocellular Carcinoma Following Checkpoint Inhibitor Therapy with Nivolumab.

Am J Transplant 2022 Jan 25. Epub 2022 Jan 25.

Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, San Diego California.

Limited case series describe conflicting results regarding the safety of checkpoint inhibitors (CPI) prior to liver transplantation (LT). We reviewed single-center data on all consecutive patients who underwent LT for hepatocellular carcinoma (HCC) treated with CPI between January 1, 2018, and January 30th, 2021. Time from CPI to LT, immunosuppression, biopsy proven acute cellular rejection (BPACR), graft loss and death were evaluated. Read More

View Article and Full-Text PDF
January 2022

The Malaysian Society of Gastroenterology and Hepatology Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease.

J Gastroenterol Hepatol 2022 Jan 25. Epub 2022 Jan 25.

Gastroenterology Unit, Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Introduction: The Malaysian Society of Gastroenterology and Hepatology saw the need for a consensus statement on metabolic dysfunction-associated fatty liver disease (MAFLD).

Methods: The consensus panel consisted of experts in the field of gastroenterology/hepatology, endocrinology, bariatric surgery, family medicine and public health. A modified Delphi process was used to prepare the consensus statements. Read More

View Article and Full-Text PDF
January 2022

Trends in Survival for Pediatric Transplantation.

Pediatrics 2022 Jan 25. Epub 2022 Jan 25.

Division of Abdominal Transplantation, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.

Objectives: Progress in pediatric transplantation measured in the context of waitlist and posttransplant survival is well documented but falls short of providing a complete perspective for children and their families. An intent-to-treat analysis, in which we measure survival from listing to death regardless of whether a transplant is received, provides a more comprehensive perspective through which progress can be examined.

Methods: Univariable and multivariable Cox regression was used to analyze factors impacting intent-to-treat survival in 12 984 children listed for heart transplant, 17 519 children listed for liver transplant, and 16 699 children listed for kidney transplant. Read More

View Article and Full-Text PDF
January 2022

Assessing differences in surgical outcomes following emergency abdominal exploration for complications of elective surgery and high-risk primary emergencies.

Sci Rep 2022 Jan 25;12(1):1349. Epub 2022 Jan 25.

Faculty of Medicine, Clinic for Visceral, Transplantation, Thoracic and Vascular Surgery, University Hospital of Leipzig, Liebig Strasse 20, 04103, Leipzig, Germany.

Irrespective of its etiology, emergency surgical abdominal exploration (EAE) is considered a high-risk procedure with mortality rates exceeding 20%. The aim of this study was to evaluate differences in outcomes in patients who required EAE due to complications of complex elective abdominal procedures and those who required EAE due to high-risk primary abdominal emergencies. Patients undergoing EAE for acute surgical complications of complex abdominal elective surgical procedures (N = 293; Elective group) and patients undergoing EAE for high-risk primary abdominal emergencies (N = 776; Emergency group) from 2012 to 2019 at our institution were retrospectively assessed for morbidity and mortality. Read More

View Article and Full-Text PDF
January 2022

Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence.

Signal Transduct Target Ther 2022 Jan 26;7(1):24. Epub 2022 Jan 26.

Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Patients with hepatocellular carcinoma (HCC) have poor long-term survival following curative resection because of the high rate of tumor early recurrence. Little is known about the trajectory of genomic evolution from primary to early-recurrent HCC. In this study, we performed whole-genome sequencing (WGS) on 40 pairs of primary and early-recurrent hepatitis B virus (HBV)-related HCC tumors from patients who received curative resection, and from four patients whose primary and recurrent tumor were extensively sampled. Read More

View Article and Full-Text PDF
January 2022

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models.

Ann Transplant 2022 Jan 26;27:e934924. Epub 2022 Jan 26.

Department of Surgical, and Transplantation Nursing, and Extracorporeal Therapies, Medical University of Warsaw, Warsaw, Poland.

Liver transplantation (LTx) is the best treatment for patients with early-stage hepatocellular carcinoma (HCC). The Milan criteria positively influenced results of liver transplantation and were adopted by the majority of cancer centers, becoming the criterion standard treatment for early-stage HCC. Despite the use of restrictive criteria, recurrence is still high, affecting between 8% and 20% of cases, and is a significant predictor of survival after LTx. Read More

View Article and Full-Text PDF
January 2022

Upper Midline Incision Could Become Standard Practice for Living Donor Right Hepatectomy.

Transplant Proc 2022 Jan 22. Epub 2022 Jan 22.

Division of Hepatobiliary Pancreas Surgery and Liver Transplantation, Department of Surgery, Catholic University of Daegu College of Medicine, Daegu, Korea.

Background: Laparoscopic approaches have not been performed in living right donor hepatectomy (LDRH) because these are more technically demanding and are associated with increased donor morbidity. Instead, several studies have described LDRH using an upper midline incision (UMI) to reduce donor morbidity. Herein, we describe our experience with small UMI as a standard procedure for LDRH. Read More

View Article and Full-Text PDF
January 2022

Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant centre: ready for prime time.

BMC Gastroenterol 2022 Jan 25;22(1):34. Epub 2022 Jan 25.

Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.

Background: Transplantation offers the best survival for patients with end stage organ disease. Transplant of hepatitis C virus (HCV) nucleic acid test (NAT) positive organs into negative recipients is a novel strategy that can expand the donor pool. We aim to evaluate our centre's experience. Read More

View Article and Full-Text PDF
January 2022

Combined Transarterial Chemoembolization with Microwave Ablation versus Microwave Alone for Treatment of Medium Sized Hepatocellular Carcinoma.

Curr Cancer Drug Targets 2022 Jan 20. Epub 2022 Jan 20.

Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Benha University, Benha, Egypt.

Background & Aims: Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths. The only definitive treatment for both HCC and cirrhosis is liver transplantation, but long wait times in some regions and a relatively fixed number of donor organs negatively impact access to liver transplantation. The aim of the work was to evaluate and compare the short outcome of patients with medium-sized HCC who will undergo percutaneous microwave ablation (MWA) alone and in combination with TACE. Read More

View Article and Full-Text PDF
January 2022

[Consensus on diagnosis and treatment of postoperative infections in pediatric liver transplant recipients].

Authors:

Zhonghua Wai Ke Za Zhi 2022 Mar 1;60(3):193-202. Epub 2022 Mar 1.

With the breakthrough in surgical technology, pediatric liver transplantation (PLT) has achieved landmark development in China in recent years. In some high-volume centers, postoperative outcomes have even been comparable to the world-leading levels. However, postoperative infection remains a major factor affecting graft and recipient survivals. Read More

View Article and Full-Text PDF

A Two-Stage Surgical Approach for Malignant Adrenocortical Carcinoma with Intracardiac Extension.

Ann Thorac Surg 2022 Jan 22. Epub 2022 Jan 22.

Hepato-Pancreato-Biliary Surgery and Liver transplantation, Pôle des Pathologies Digestives, Hépatiques et de la Transplantation, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.

Direct intracardiac extensions by abdominal malignancies represent a rare but challenging situation. Removal of the intracardiac extension requires cardiopulmonary bypass with systemic anticoagulation, which could potentially increase the risk of bleeding if associated with liver resection. We describe a two-stage surgical approach for malignancy with intracardiac extension in a high-risk situation. Read More

View Article and Full-Text PDF
January 2022

Therapeutic efficacy of FASN inhibition in preclinical models of HCC.

Hepatology 2022 Jan 25. Epub 2022 Jan 25.

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.

Background & Aims: Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a novel FASN inhibitor, either alone or in combination, for HCC treatment.

Approach & Results: The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-PD-L1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models. Read More

View Article and Full-Text PDF
January 2022

Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.

J Cancer Res Clin Oncol 2022 Jan 25. Epub 2022 Jan 25.

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, INF 110, 69120, Heidelberg, Germany.

Purpose: We assessed and compared clinical effects and safety endpoints of three methods of transarterial chemoembolization (TACE), conventional (cTACE), with drug-eluting beads (DEB-TACE), and with degradable starch microspheres (DSM-TACE), used in patients with hepatocellular carcinoma (HCC) in the bridging to liver transplant (LT) and the palliative setting.

Methods: In our center, 148 patients with HCC underwent 492 completed TACE procedures between 2008 and 2017 (158 for bridging to LT; 334 for palliative treatment) which we analyzed retrospectively. Of these procedures, 348 were DEB-TACE, 60 cTACE, and 84 DSM-TACE. Read More

View Article and Full-Text PDF
January 2022

Proposed hypothesis of GSK-3 β inhibition for stimulating Wnt/β-catenin signaling pathway which triggers liver regeneration process.

Naunyn Schmiedebergs Arch Pharmacol 2022 Jan 25. Epub 2022 Jan 25.

Chitkara College of Pharmacy, Chitkara University, Punjab, India.

Almost every human organ has a poor ability to regenerate, notable exceptions are liver, skin, gut, etc. Molecular and cellular underpinnings of liver regeneration might pave the way for novel treatments concerned with chronic liver disorder. Such treatments would eliminate the disadvantages of liver transplantation, such as a scarcity of donor organs, a lengthy waitlist, significant medical expenses, surgical complications, and the necessity for lifelong immunosuppressive medications. Read More

View Article and Full-Text PDF
January 2022

A Novel Scoring System in Predicting Prognosis After Adjuvant FOLFOX Chemotherapy in Gastric Cancer.

Cancer Biother Radiopharm 2022 Jan 25. Epub 2022 Jan 25.

Department of Liver Transplantation and Hepatic Surgery, Cheeloo College of Medicine, Shandong University, Shandong Qianfoshan Hospital, Jinan, China.

To evaluate the impact of neutrophil-to-lymphocyte ratio (NLR) and preoperative prognostic nutritional index (PNI) on prognosis of gastric cancer (GC) after adjuvant FOLFOX chemotherapy. Data on 749 GC patients who received operation after by adjuvant FOLFOX chemotherapy between January 2013 and December 2015 were enrolled in this study, retrospectively. Receiver-operating characteristic curve analysis was employed to assess optimal cutoff thresholds for PNI and NLR. Read More

View Article and Full-Text PDF
January 2022

Importance of daptomycin dosage on the clinical outcome in liver transplant recipients with vancomycin-resistant enterococci infection.

J Chemother 2022 Jan 25:1-8. Epub 2022 Jan 25.

Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

We retrospectively studied 16 (3 colonization and 13 infections) early post-liver transplant (≤60-day after transplantation) patients with vancomycin-resistant enterococci (VRE) colonization/infection from 2016 to 2019. All VRE isolates were . Of 13 patients with VRE infection, 12 (92. Read More

View Article and Full-Text PDF
January 2022

Perioperative Cangrelor in Patients with Recent Percutaneous Coronary Intervention Undergoing Liver Transplantation: A Case Series.

Pharmacotherapy 2022 Jan 25. Epub 2022 Jan 25.

J.C. Walter, Jr. Transplant Center, Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, Texas, USA.

Background: Management of dual antiplatelet therapy (DAPT) in the perioperative setting is challenging, particularly in complex patient populations, such as those with underlying coagulopathy and/or recent percutaneous coronary interventions.

Methods: In this case series, we describe the perioperative use of cangrelor bridge therapy in two patients undergoing liver transplantation after recent coronary drug-eluting stent placement.

Outcomes: In both patient cases, cangrelor use as a P2Y12 bridge at a dose of 0. Read More

View Article and Full-Text PDF
January 2022

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.

Biosci Rep 2022 Jan 25. Epub 2022 Jan 25.

Chinese Academy of Sciences Hefei Institutes of Physical Science, Hefei, China.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide. The onset of the disease is occult and develops rapidly. As a result, the disease is often detected when it is already in advanced stages, resulting in patients losing the best opportunity for liver transplantation and surgical treatment. Read More

View Article and Full-Text PDF
January 2022

Transplantation of 3D adipose-derived stem cell/hepatocyte spheroids alleviates chronic hepatic damage in a rat model of thioacetamide-induced liver cirrhosis.

Sci Rep 2022 Jan 24;12(1):1227. Epub 2022 Jan 24.

Department of Biomedical Engineering, I-Shou University, Kaohsiung City, Taiwan.

Cirrhosis refers to irreversible liver damage where healthy tissue is replaced by scar tissue, resulting in impaired liver function. There is no cure and current treatments only prevent further liver damage; thus, novel therapeutic options are urgently needed. Here, we report a new approach that enables the formation of self-assembled 3D spheroids of adipose-derived stem cells (ADSCs) and murine hepatocytes (AML12) via reconstituted collagen fibers. Read More

View Article and Full-Text PDF
January 2022

In vivo modeling of patient genetic heterogeneity identifies new ways to target cholangiocarcinoma.

Cancer Res 2022 Jan 24. Epub 2022 Jan 24.

MRC Human Genetics Unit, University of Edinburgh

Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy of the bile ducts within the liver characterized by high levels of genetic heterogeneity. In the context of such genetic variability, determining which oncogenic mutations drive ICC growth has been difficult, and developing modes of patient stratification and targeted therapies remains challenging. Here we model the interactions between rare mutations with more common driver genes and combine in silico analysis of patient data with highly multiplexed in vivo CRISPR-spCas9 screens to perform a functional in vivo study into the role genetic heterogeneity plays in driving ICC. Read More

View Article and Full-Text PDF
January 2022

Pyrvinium pamoate ameliorates cyclosporin A- induced hepatotoxicity via the modulation of Wnt/β-catenin signaling and upregulation of PPAR-γ.

Int Immunopharmacol 2022 Jan 21;104:108538. Epub 2022 Jan 21.

Pharmacology and Toxicology department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

Background: Cyclosporin A (CsA) is an immunosuppressive agent that can be used to treat autoimmune diseases. Despite its hepatotoxicity, CsA is a backbone in organ transplantation. Pyrvinium pamoate (PP) is an inhibitor of Wnt signaling approved by the U. Read More

View Article and Full-Text PDF
January 2022

[Kidney damage in liver transplantation: A frequent and ongoing concern].

Authors:
Antoine Durrbach

Nephrol Ther 2022 Jan 21. Epub 2022 Jan 21.

Inserm U1186, institut Gustave-Roussy, hôpital Henriè-Mondor, Créteil, France. Electronic address:

View Article and Full-Text PDF
January 2022